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Abstract
Background:  Irreversible airflow obstruction in Chronic Obstructive Pulmonary Disease
(COPD) is thought to result from airway remodelling associated with aberrant inflammation.
Patients who experience frequent episodes of acute deterioration in symptoms and lung function,
termed exacerbations, experience a faster decline in their lung function, and thus over time greater
disease severity However the mechanisms by which these episodes may contribute to decreased
lung function are poorly understood.
This study has prospectively examined changes in sputum levels of inflammatory cells, MMP-9 and
TIMP-1 during exacerbations comparing with paired samples taken prior to exacerbation.
Methods: Nineteen COPD patients ((median, [IQR]) age 69 [63 to 74], forced expiratory volume
in one second (FEV1) 1.0 [0.9 to1.2], FEV1% predicted 37.6 [27.3 to 46.2]) provided sputa at
exacerbation. Of these, 12 were paired with a samples collected when the patient was stable, a
median 4 months [2 to 8 months] beforehand.
Results: MMP-9 levels increased from 10.5 µg/g [1.2 to 21.1] prior to exacerbation to 17.1 µg/g
[9.3 to 48.7] during exacerbation (P < 0.01). TIMP-1 levels decreased from 3.5 µg/g [0.6 to 7.8] to
1.5 µg/g [0.3 to 4.9] (P = 0.16). MMP-9/TIMP-1 Molar ratio significantly increased from 0.6 [0.2 to
1.1] to 3.6 [2.0 to 25.3] (P < 0.05). Neutrophil, eosinophil and lymphocyte counts all showed
significant increase during exacerbation compared to before (P < 0.05). Macrophage numbers
remained level. MMP-9 levels during exacerbation showed highly significant correlation with both
neutrophil and lymphocyte counts (Rho = 0.7, P < 0.01).
Conclusion: During exacerbation, increased inflammatory burden coincides with an imbalance of
the proteinase MMP-9 and its cognate inhibitor TIMP-1. This may suggest a pathway connecting
frequent exacerbations with lung function decline.
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Background
Chronic obstructive pulmonary disease (COPD) is a clas-
sic disease of airway damage and remodelling, character-
ised by slowly progressive airflow obstruction, resulting in
increasing dyspnoea and exercise limitation. It is a widely
accepted theory that an important causative factor is extra-
cellular matrix (ECM) remodelling, resulting from aber-
rant inflammation and disruption of the proteinase –
antiproteinase balance; reviewed [1]. The identity of can-
didate proteinases has been a subject of much debate,
however the balance between matrix metalloproteinases
(MMPs) and their inhibitors; the tissue inhibitors of met-
alloproteinase (TIMPs), is thought to be important in
pathogenesis [1-3].
MMPs are a family of up to 26 homologous endopepti-
dases, which can collectively degrade all of the protein
components of the extracellular matrix [4]. They are pro-
duced by a range of stromal cells and by two of the major
inflammatory cells implicated in COPD – neutrophils
and alveolar macrophages [5,6]. Recent studies have
shown that levels of MMPs, especially MMP-9, are ele-
vated in the bronchial alveolar lavage (BAL) fluid from
patients with COPD, compared to normal controls [5,7],
and high levels of both MMP-9 and its cognate inhibitor
TIMP-1 have been found in sputum from chronic bron-
chitics [8] and correlated with decrease in lung function
[9,10]. While these studies focused on stable COPD, there
has been no analysis to date of MMP-9 and TIMP-1 varia-
tion during exacerbations.
Patients with moderate to very severe COPD are prone to
frequent exacerbations, which are associated with a
poorer health-related quality of life [11]. Exacerbations
can be triggered by viral or bacterial infection of the lower
respiratory tract [12,13] both of which increase airway
and systemic inflammatory response [14-16]. Exacerba-
tions also contribute to the accelerated decline in FEV1
that is characteristic of COPD [17,18].
Using a well monitored group of COPD patients, this
study has prospectively investigated changes in sputum
levels of MMP-9 and TIMP-1 during exacerbations in
COPD and compared these to samples taken from the
same individuals prior to exacerbation. The aim of the
study was to see whether the MMP/TIMP balance was
upset during exacerbation as this might suggest a pathway
between exacerbations, ECM remodelling and lung func-
tion decline.
Methods
Subjects
Nineteen patients were recruited from a cohort of patients
followed since October 1995 by the East London COPD
study [14,19]. Inclusion criteria and enrolment for the
study have been previously published [14,19].
The patients were recording on diary cards each morning
any increase over their normal, stable condition of (i) dys-
pnoea, sputum purulence or sputum volume (major
symptoms) and (ii) colds (nasal discharge/congestion),
wheeze, sore throat, cough and fever (minor symptoms).
This was a yes/no answer. Exacerbation onset was identi-
fied as the first of two or more consecutive days with
increase in either two or more major symptoms, or any
one major symptom plus any minor symptom. The pro-
spective data collected on the diary cards before and at
onset of the exacerbation showed that peak expiratory
flow fell from 246 l/min (223 to 313) averaged over days
14-8 preceding exacerbation by 7.1 l/min (-22 to 3) on the
day of onset. Similarly, the number of symptoms rose
from zero to 2 (2 to 3) on the day of onset. Patients with
any deterioration of symptoms were encouraged to con-
tact the clinical team by telephone, and were seen in clinic
for sputum sampling, generally within 48 hours. Patients
also attended 3 monthly clinics at which samples were
obtained when the patient was exacerbation free (clini-
cally stable).
19 individuals (Table 1) were recruited and gave
informed, written consent. 12 of the 19 samples taken at
exacerbation were paired with a prospectively collected
stable sample obtained within a median of 4 months
(IQR 2–8 months) prior to the sampled exacerbation. The
study had ethics approval from the Ethics Committee of
the East London and City Health Authority.
Table 1: Characteristics of the 19 patients in the study
Median IQR
Age, yr 69 63 to 74
FEV1, L (stable) 1.0 0.9 to 1.2
FEV1, % 37.6 27.3 to 46.2
FEV1/FVC 45.2 25.9 to 54.8
pO2 (kPa) 9.27 8.45 to 9.51
pCO2 (kPa) 5.66 5.49 to 6.36
O2 saturation breathing room air (%) 94 92 to 95
Reversibility to salbutamol (%) 9.7 5.0 to 13.5
%
Males 85
Ex smokers 60
Current smokers 40
Daily taking oral steroids 5
Daily taking inhaled steroids 90Respiratory Research 2005, 6:151 http://respiratory-research.com/content/6/1/151
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Sputum preparation
Sputum samples were processed as per Bhowmik et al
2000 [14]. Briefly, the sputum was incubated with four
times its weight of 0.01 M DTT in HBSS, at 4°C for 15
minutes. Sputum dilution was in proportion to the weight
collected thus standardizing between time points and
patients the supernatants used for assay of proteinases
and other markers. The volume of HBSS was then doubled
(ten fold dilution of original sputum sample) and incu-
bated for a further 5 minutes. The suspension was then fil-
tered through 50 µm nylon gauze to remove mucus and
debris without removing any of the cells and centrifuged
at 790 g for 10 minutes. The cell free supernatant was
removed and stored at -70°C. The cell pellet was resus-
pended. The total cell count was determined with a Neu-
bauer haemocytometer using the trypan blue exclusion
method to determine cell viability, blue cells were
counted as non viable. Cytospins were made from the cell
suspension and stained with Diff-Quik to obtain a differ-
ential cell count.
Zymography
Quantitative gelatin zymography was carried out as
described by Kleiner et al [20] to analyse MMP-9 levels.
Briefly, samples were prepared by dilution into a 5X
zymography sample buffer consisting of 0.4 M Tris, pH
6.8, 5% SDS, 12.5% sucrose, and 0.03% bromophenol
blue. 10 µl volumes of sample were loaded onto a 7.5%
polyacrylamide gel containing 0.1% gelatin and the pro-
teins separated by electrophoresis. The gel was washed
twice in buffer containing 20 mM Tris, and 2.5% Triton,
pH 7.8 and incubated overnight at 37°C in Tris/Triton
buffer supplemented with 10 mM CaCl2 and 5 µM ZnCl.
The following day the gels were stained with 0.5%
Coomassie and the gelatinases visualised as clear areas on
a dark blue background (see Figure 1). The major band of
MMP-9 activity in all samples was proMMP-9 observed at
92 kDa, this accounted for a median 92% of total MMP-9
activity (total n = 31 samples, IQR 78–100%). Additional
bands were also observed at 125 kDa and 220 kDa com-
prising MMP-9 complexed with inhibitors and MMP-9
dimers. In a small minority of samples active MMP-9 was
observed below the major MMP-9 band at 82 kDa. MMP-
2 activity was found to migrate to 72 kDa. The identity of
MMP-9 was further verified by immunoprecipitation with
a polyclonal antibody to MMP-9 (4 mg/ml, Biogenesis.
Dorset, UK) Figure 1.
Band intensity was captured and digitised by scanning
densitometry (using scan analysis). The optical optical
density for each band of interest was calculated as area
under curve. This value was converted to total MMP-9 for
each patient by combining the values for each band (220,
125 and 92 kDa) and normalizing to MMP-9 standard (1
ng/lane, Biogenesis. Dorset, UK) (see Figure 1). Samples
outside of the accurate limit of detection were diluted up
to a hundred fold and rerun.
Analysis of TIMP-1
Samples were analysed using a commercial Biotrak® TIMP-
1 ELISA (Amersham Biosciences. Bucks. UK.) specific for
both total free TIMP-1 and TIMP-1 complexed to MMPs.
ELISAs were run according to the manufacturer's instruc-
tions.
Statistical analyses
All differences within sets of paired data were analysed
using the non-parametric Wilcoxon signed rank test. Cor-
relations were calculated using the non-parametric Spear-
man correlation. P  value < 0.05 was considered
significant.
Results
Levels of MMP-9 and TIMP-1 in paired samples
Figure 2 shows that total MMP-9 levels increased from a
median of 10.5 µg/g (IQR 1.2 to 21.1) prior exacerbation
to 17.1 µg/g (IQR 9.3 to 48.7) during exacerbation (P <
0.01) (n = 12). Additionally, the percentage of samples
showing an active MMP-9 band (running at 82 kDa) was
Sample zymogram showing immunoprecipitation of MMP-9  from sputum Figure 1
Sample zymogram showing immunoprecipitation of 
MMP-9 from sputum. 10 µl volumes loaded per lane. Lane 
1: High range molecular weight markers (Amersham Bio-
sciences); lane 2: polyclonal antiMMP-9 (4 µg/ml); lane 3: 
exacerbation sputum sample (1:100 dilution) + antiMMP-9 (4 
µg/ml); lane 4: exacerbation sputum sample (1:100 dilution); 
lane 5: pro-MMP-9 standard (92 kDa) (100 ng/ml).Respiratory Research 2005, 6:151 http://respiratory-research.com/content/6/1/151
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observed in 1 paired sample prior to exacerbation com-
pared to 4 during exacerbation (data not shown). Of the
total of 19 samples taken during exacerbation, 7 showed
an active MMP-9 (82 kDa) band.
In contrast, median levels of TIMP-1 decreased from 3.5
µg/g (IQR 0.6 to 7.8) to 1.5 µg/g (IQR 0.3 to 4.9), with
this change approaching statistical significance (P = 0.16).
Proteinase/antiproteinase imbalance at exacerbation (Fig-
ure 3) is reflected by a change in the MMP-9/TIMP-1
molar ratio from a median of 0.6 (IQR 0.2 to 1.1) before
to 3.6 (IQR 2.0 to 25.3) during exacerbation (P < 0.05).
Levels of MMP-2 were also analysed by gelatin zymogra-
phy, however out of all sputum samples analysed only
one showed a small amount of MMP-2 activity (data not
shown).
MMP-9 and cellular inflammation
Figure 4 indicates that total cell influx into sputum
increases significantly during exacerbation (P < 0.05). Fig-
ure 4 and table 2 show that neutrophil, eosinophil and
lymphocyte numbers all increase significantly during
exacerbation, compared with pre exacerbation levels. In
contrast macrophage numbers remained unchanged and
show a significant decrease as a proportion of total cells.
Percentage squamous cell contamination of sputum var-
ied from 5.14% (IQR 1.81–6.20) during stable COPD, to
1.6% (0.43–4.58) during exacerbation (data not shown).
Figure 5 and table 3 show that during exacerbation (n =
25) MMP-9 correlates significantly with levels of both
neutrophils and lymphocytes (Rho = 0.7,P < 0.005 for
both cell types). Correlation between MMP-9 and macro-
phages or eosinophils did not reach the same level of sig-
MMP-9 and TIMP-1 levels in sputum from COPD patients Figure 2
MMP-9 and TIMP-1 levels in sputum from COPD patients. Samples were taken from patients prior to and during exac-
erbation (n = 12). MMP-9 was measured by gelatin zymography and TIMP-1 was measured by ELISA and corrected for weight 
of sputum. Individuals are shown as open circles and median values as diamonds. Data were analysed by non parametric Wil-
coxon signed rank test.
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nificance (Rho = 0.5 P < 0.1 for macrophages and Rho =
0.5 P < 0.05 for eosinophils). No relationship was found
between MMP-9 and any cell type in any of the paired
sputa obtained prior to exacerbation when the patient was
clinically stable (Data not shown).
Discussion
This is the first pilot study to look at how levels of the
inflammatory proteinase, MMP-9 and its cognate inhibi-
tor, TIMP-1 change in the airway during an exacerbation.
The results indicate that exacerbations are associated with
an increase in MMP-9 burden in the airways. This increase
could result in ECM destruction in the airways and con-
tributing to airway remodelling and the decline in lung
function seen in COPD patients. Previous studies have
related MMP-9 to parenchymal destruction and lung func-
tion decline, in sub clinical [5] and established emphy-
sema [7]. Studies with induced sputum from stable COPD
patients have found that levels of MMP-9 and TIMP-1 are
elevated in COPD patients compared to controls [9,10].
Levels were found to correlate with both increased neu-
trophilia and decrease in lung function. These studies sug-
gest that an underlying proteolytic environment exists in
the airways in COPD, however studies where molar ratio
of MMP-9 to TIMP-1 was analysed found that TIMP-1 lev-
els outweighed MMP-9 [8,21]. Our current study indicates
that prior to exacerbation MMP-9/TIMP-1 balance favours
the inhibitor. During exacerbation however MMP-9 levels
significantly increase, tipping the balance in favour of
MMP-9. A similar finding has been reported in asthmatic
exacerbations which found that circulating levels of MMP-
9 were increased in patients during exacerbation com-
pared with convalescence [22]. The frequency of shift
between a "proteolytic" phenotype during exacerbation
and "fibrotic" phenotype outside exacerbation, may be an
important driving factor in airway remodelling, and
deserves further research.
Our data show that number of neutrophils, eosinophils,
and lymphocytes all increase in the airways during an
exacerbation, whilst levels of macrophages remained con-
stant. Recent studies have shown that alveolar macro-
phages from smokers increased production of MMP-9 in
response to cigarette smoke conditioned medium [23].
Pro-inflammatory stimuli such as IL-1β and LPS also
increased MMP-9 production, leading the authors to sug-
gest that Alveolar Macrophage release of MMP-9 could
have relevance in COPD exacerbations. In this present
study, a strong correlation was observed during exacerba-
tion between increased neutrophil number and MMP-9
while a weaker association existed between macrophages
and MMP-9. While the contribution of macrophage
derived MMP-9 cannot be ruled out, it is tempting to spec-
ulate from these data that neutrophil influx is the primary
source of increased MMP-9 during exacerbation. The stim-
ulus for increased neutrophil influx was not assessed in
this study, however it seems likely that neutrophil specific
chemokines such as IL8 are involved this response.
Recently, Bhowmik et al, using sputa from the East Lon-
don COPD study, reported that levels of IL8 during exac-
erbation were related to neutrophil number [14].
Additionally, it is of note that the increase in MMP-9 dur-
ing exacerbation also shows a very close association with
increase in lymphocyte number. It is unclear whether
these events are related; however it is pertinent to suggest
that the increase in neutrophil and lymphocyte numbers
is linked. In support of this concept, a recent study in mice
has shown that intranasal stimulation by the cytokine
IL17, produced by CD4+ T-lymphocytes induced a pro-
nounouned accumulation in both pro and active MMP-9
associated with local accumulation of neutrophils [24]. A
recent study by Zhu et al reported an increase in the
number of CD4+ lymphocytes in the airways during exac-
erbation in COPD [25]. The authors suggested that virally
induced upregulation of the chemokine RANTES during
Molar ratio between MMP-9 and TIMP-1 in COPD sputum Figure 3
Molar ratio between MMP-9 and TIMP-1 in COPD 
sputum. The data from figure 2 was used to calculate a 
molar ratio between MMP-9 and TIMP-1. Median values are 
marked as diamonds. Data were statistically analysed by a 
non parametric Wilcoxon signed rank test.
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Inflammatory cell counts prior to and during exacerbation Figure 4
Inflammatory cell counts prior to and during exacerbation. Differential neutrophil, eosinophil, lymphocyte and macro-
phage counts were carried out on samples from COPD patients and corrected for weight of sputum. Samples were taken from 
patients prior to and during exacerbation (n = 12). Median cell counts are marked as diamonds. Data were analysed by a non 
parametric Wilcoxon signed rank test.
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exacerbation could contribute to this. In addition an
increased airway eosinophilia, also attributed to RANTES
upregulation, was observed.
While eosinophils do not have a clearly defined role in
COPD, an increased airway eosinophilia during exacerba-
tion has now been observed in a range of studies includ-
ing our own [16,25]. The role of eosinophils in disease
progression may therefore deserve further investigation.
Previous studies using asthmatic BAL identified eosi-
nophils as important sources of MMP-9 [26]. However a
comparatively weak, albeit significant association
between MMP-9 and eosinophils in our study, suggests
eosinophils are not the primary source of MMP-9 during
COPD exacerbation.
Table 2: Total and differential leukocyte cell counts in COPD sputum sampled prior to and during exacerbation† (n = 12)
Cell type Pre-exacerbation Exacerbation P-value
Median IQR Median IQR
Total cell (106 cells/g) 1.61 0.88–2.25 2.86 1.64–7.2 <0.01
% viability 65.14 56.05–74.92 83.33 65.57–88.60 <0.01
Neutrophil (106 cells/g) 1.48 0.84–2.02 2.19 1.10–6.16 <0.05
% Neutrophils 80.0 72.63–89.30 87.5 78.38–89.25 NS
Macrophage (106 cells/g) 0.23 0.13–0.25 0.26 0.15–0.42 NS
% Macrophages 17.25 6.63–22.25 6.0 5.38–17.5 <0.05
Eosinophil (106 cells/g) 0.01 0.002–0.03 0.07 0.02–0.10 <0.01
% Eosinophils 0.75 0.25–1.38 1.0 0.63–3.00 NS
Lymphocyte (106 cells/g) 0.03 0.02–0.07 0.13 0.05–0.3 <0.05
% Lymphocytes 2.50 1.38–4.38 4.5 1.25–5.63 NS
† Paired sputa from 12 individuals.
Relationship between cell infiltration and MMP-9 in COPD sputum during an exacerbation Figure 5
Relationship between cell infiltration and MMP-9 in COPD sputum during an exacerbation. Neutrophil (Left hand 
panel) and lymphocyte (right hand panel) counts were carried out on sputum samples from COPD patients during exacerba-
tion (n = 19), and corrected for weight of sputum. Measurement of MMP-9 levels was carried out on cell free sputum superna-
tants. Cell count data were expressed as million cells/g (log scale) and MMP-9 data as µg/g.
Neutrophils (million cells /g sputum)
0.1 1 10 100
M
M
P
-
9
 
(
P
g
/
g
 
s
p
u
t
u
m
)
0
20
40
60
80
100
120
Lymphocytes (million cells /g sputum)
0.001 0.01 0.1 1
M
M
P
-
9
 
(
P
g
/
g
 
s
p
u
t
u
m
)
0
20
40
60
80
100
120Respiratory Research 2005, 6:151 http://respiratory-research.com/content/6/1/151
Page 8 of 9
(page number not for citation purposes)
Conclusion
We report here that during an exacerbation in COPD there
is an increased MMP-9 burden in the airways, which com-
bined with unchanging TIMP-1 leads to MMP-9/TIMP-1
imbalance in favour of MMP-9. Increase in MMP-9 corre-
lates with influx in both neutrophils and lymphocytes and
to a lesser extent eosinophil and macrophage numbers.
The cross talk between these cells during exacerbation and
their contribution to airway remodelling requires further
detailed investigation.
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